|
Clinical study of AdV-tk radiogene therapy for malignant glioma
|
5R44CA107745-04
|
$794,415
|
$397,208
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-12
|
$1,200,734
|
$600,367
|
Albelda, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Infectivity Enhanced Virotherapy For Ovarian Cancer
|
5R21CA128222-02
|
$275,500
|
$275,500
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer
|
1R21CA130241-01A1
|
$330,678
|
$330,678
|
ARGIRIS, ATHANASSIOS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-22
|
$1,906,536
|
$19,065
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-09
|
$2,180,816
|
$436,163
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
5R21CA116127-02
|
$168,750
|
$168,750
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Monitoring of advanced virotherapy for ovarian cancer
|
5R01CA121187-02
|
$275,500
|
$90,915
|
Curiel, David
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Targeting Retroviral DNA Integration: Role of Host Cell Proteins
|
1R21CA135214-01
|
$208,575
|
$104,288
|
DANIEL, RENE
|
THOMAS JEFFERSON UNIVERSITY
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-08
|
$2,489,653
|
$497,931
|
DINNEY, COLIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
PET IMAGING OF MART TCR-ENGINEERED CD8 T CELL IMMUNOTHERAPY IN MAN
|
5R01CA129816-02
|
$292,600
|
$292,600
|
ECONOMOU, JAMES
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Nevada Cancer Research Foundation-Community Clinical Oncology Program
|
5U10CA035421-25
|
$779,758
|
$7,798
|
ELLERTON, JOHN
|
SOUTHERN NEVADA CANCER RESEARCH FDN
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$4,812
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
3P01CA030206-26S1
|
$86,513
|
$17,303
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
5P01CA030206-26
|
$2,908,648
|
$581,730
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Molecular Gene and Radiation Therapies for Cancer
|
5P01CA097012-05
|
$1,350,392
|
$337,598
|
FREYTAG, SVEND
|
HENRY FORD HEALTH SYSTEM
|
|
Imaging Cytolytic T Cells in Cancer Patients Using PET Reporter Genes/Reporter Pr
|
1R01CA135486-01
|
$270,000
|
$270,000
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
Kansas City Clinical Oncology Program CCOP
|
5U10CA035176-25
|
$630,725
|
$6,307
|
Gaur, Rakesh
|
KANSAS CITY CLINICAL ONCOLOGY PROGRAM
|
|
Greenville SC CCOP
|
5U10CA067663-13
|
$896,435
|
$8,964
|
Giguere, Jeffrey
|
ONCOLOGY & HEMATOLOGY ASSOCIATES OF SC
|
|
Phase I Trials of Anti-Cancer Agents
|
2U01CA076576-11
|
$725,427
|
$79,797
|
GREVER, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Community Clinical Oncology Program
|
2U10CA035199-25
|
$484,645
|
$4,846
|
GRINBLATT, DAVID
|
EVANSTON NORTHWESTERN HEALTHCARE
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-22
|
$1,042,698
|
$10,427
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-09
|
$1,890,657
|
$472,664
|
HERSCHMAN, HARVEY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Enhancing T Cell Therapy of Cancer
|
2P01CA094237-06
|
$1,905,870
|
$362,115
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Gene Therapy for Brain Tumors
|
3P01CA069246-12S1
|
$41,424
|
$14,498
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Gene Therapy for Brain Tumors
|
5P01CA069246-12
|
$1,371,426
|
$479,999
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-09
|
$3,860,269
|
$772,054
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Syracuse Hematology-Oncology CCOP
|
5U10CA045389-22
|
$575,881
|
$5,759
|
KIRSHNER, JEFFREY
|
HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY
|
|
Illinois Oncology Research Association CCOP
|
5U10CA035113-25
|
$938,655
|
$9,387
|
KUGLER, JOHN
|
ONCOLOGY-HEMATOLOGY ASSOC-CENTRAL ILL
|
|
GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM
|
5U10CA035178-25
|
$1,198,666
|
$11,987
|
Lange, Marianne
|
SPECTRUM HEALTH HOSPITALS
|
|
Clinical and Laboratory Studies of Malignant Lymphomas
|
5P01CA034233-24
|
$1,681,253
|
$201,750
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
Targeting the Tumor Vasculature to Treat Cancer
|
Z01 SC 010368
|
$975,628
|
$97,563
|
Libutti, Steven
|
CCR (NCI)
|
|
MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA045564-22
|
$652,654
|
$6,527
|
Lilenbaum, Rogerio
|
MOUNT SINAI MEDICAL CENTER (MIAMI BEACH)
|
|
Heartland Cancer Research CCOP
|
2U10CA114558-04
|
$776,180
|
$7,762
|
LYSS, ALAN
|
MISSOURI BAPTIST MEDICAL CENTER
|
|
Biology & Transplantation of the Human Stem Cell
|
5P01CA065493-14
|
$2,080,053
|
$1,040,027
|
MCGLAVE, PHILIP
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
University of Texas SPORE in Lung Cancer
|
2P50CA070907-11
|
$2,300,000
|
$69,000
|
MINNA, JOHN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
SPORE In Protate Cancer
|
2P50CA058236-14
|
$2,300,000
|
$69,000
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Peptide Synthesis Core Faciity and Peptide Epitope Identification
|
Z01 BC 011030
|
$294,609
|
$147,305
|
Parkhurst, Maria
|
CCR (NCI)
|
|
Minority Based Community Clinical Oncology Program
|
5U10CA074811-11
|
$936,500
|
$9,365
|
PEACE, DAVID
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-07
|
$707,872
|
$141,574
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
VCU Minority-Based CCOP
|
5U10CA052784-18
|
$577,110
|
$5,771
|
ROBERTS, JOHN
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
Z01 BC 010984
|
$1,116,265
|
$446,506
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Gene therapy of cancer
|
Z01 BC 010985
|
$1,116,265
|
$446,506
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Genetic Approaches to Cancer Immunotherapy
|
5P01CA059350-15
|
$1,998,048
|
$259,746
|
SADELAIN, MICHEL
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Cancer and Leukemia Group B
|
5U10CA037447-25
|
$1,580,095
|
$63,204
|
SCHILSKY, RICHARD
|
UNIVERSITY OF CHICAGO
|
|
SPORE in Prostate Cancer
|
5P50CA091956-08
|
$2,179,681
|
$435,936
|
TINDALL, DONALD
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Activity & resistance of Gleevec in GI stromal tumors
|
5K23CA109060-05
|
$136,080
|
$68,040
|
TRENT, JONATHAN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
North Shore CCOP
|
5U10CA035279-25
|
$422,875
|
$4,229
|
VINCIGUERRA, VINCENT
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
|
Pediatric Oncology Branch Clinical Care and Education
|
Z01 BC 010764
|
$1,703,170
|
$17,032
|
Wayne, Alan
|
CCR (NCI)
|
|
Cell Prep Core
|
Z01 BC 010905
|
$868,123
|
$434,062
|
Wunderlich, John
|
CCR (NCI)
|
Total relevant funding to Gene Therapy Clinical Trials for this search: $10,763,892
|